The Primitive Neuroectodermal Tumor (PNET) drugs in development market research report provides comprehensive information on the therapeutics under development for Primitive Neuroectodermal Tumor (PNET), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primitive Neuroectodermal Tumor (PNET). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primitive Neuroectodermal Tumor (PNET) and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Primitive Neuroectodermal Tumor (PNET) by nine companies/universities/institutes. The top development phase for Primitive Neuroectodermal Tumor (PNET) is phase i with four drugs in that stage. The Primitive Neuroectodermal Tumor (PNET) pipeline has seven drugs in development by companies and two by universities/ institutes. Some of the companies in the Primitive Neuroectodermal Tumor (PNET) pipeline products market are: Eisai, Chimerix and MacroGenics.

The key targets in the Primitive Neuroectodermal Tumor (PNET) pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Transforming Growth Factor Beta (TGFb) , and Tubulin .

The key mechanisms of action in the Primitive Neuroectodermal Tumor (PNET) pipeline product include Tubulin Inhibitor with one drug in Phase II. The Primitive Neuroectodermal Tumor (PNET) pipeline products include seven routes of administration with the top ROA being Intravenous and five key molecule types in the Primitive Neuroectodermal Tumor (PNET) pipeline products market including Cell Therapy, and Monoclonal Antibody.

Primitive Neuroectodermal Tumor (PNET) overview

Primitive neuroectodermal tumors (PNET) and pineoblastoma are a group of tumors defined by their appearance and are thought to develop from undeveloped nerve cells in the brain. They are aggressive tumors that tend to attach to parts of the brain that control movement, thought, and sensation.

For a complete picture of Primitive Neuroectodermal Tumor (PNET)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.